SGLT2 inhibitors are a class of diabetes medications that lower blood sugar by blocking the kidneys from reabsorbing glucose, causing it to leave the body through urine. But their impact stretches far beyond blood sugar control. Large trials have shown they reduce heart failure hospitalizations, slow the progression of chronic kidney disease, and lower cardiovascular death, even in people who do not have diabetes. These wide-ranging benefits have turned what began as a glucose-lowering drug into one of the most consequential medication classes in modern cardiology and nephrology.
How They Work
Your kidneys filter roughly 180 grams of glucose from your blood every day and, under normal conditions, reabsorb almost all of it back into the bloodstream. A protein called sodium-glucose cotransporter 2, sitting in the early part of the kidney’s filtration tubes, handles the bulk of that reabsorption. SGLT2 inhibitors block that protein, so a meaningful portion of filtered glucose passes into your urine instead of being recycled. The result is a direct calorie loss and a drop in blood sugar that does not depend on insulin.
Because the mechanism is insulin-independent, it works regardless of how much insulin your pancreas makes or how resistant your tissues are to it. The drugs also act as mild diuretics: blocking sodium-glucose reabsorption pulls extra sodium and water into the urine, which lowers blood volume and blood pressure.1PubMed. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors This combination of lower glucose, less fluid, and reduced blood pressure sets up a cascade of downstream benefits that researchers are still cataloging.
Protecting the Heart
The cardiovascular story is what elevated SGLT2 inhibitors from a “just another diabetes pill” status to front-line therapy for heart failure. A large meta-analysis found that SGLT2 inhibitors reduced the combined risk of cardiovascular death, heart failure hospitalizations, and urgent heart failure visits across a remarkably wide range of patients: men and women, people younger and older than 65, Black and White patients, those with reduced or preserved heart pumping ability, and those with or without significant kidney impairment.2EClinicalMedicine. Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis That consistency across subgroups is unusual for a heart failure treatment and is a major reason guidelines now recommend these drugs for heart failure patients whether or not they have diabetes.
How they protect the heart is still debated, but several mechanisms are likely at play. By acting as a mild diuretic, SGLT2 inhibitors reduce the volume overload that strains a failing heart. The metabolic shift also matters: when the kidneys dump glucose, the body compensates partly by burning more fat and producing ketone bodies, which the heart muscle may use as a more efficient fuel than glucose or fatty acids alone.3PubMed Central. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure Research into the exact contribution of ketones to the cardiac benefits is ongoing, but the theory helps explain why these drugs work so well in heart failure specifically, where the heart is energy-starved.
Slowing Kidney Disease
If the heart failure data were impressive, the kidney data are equally striking. SGLT2 inhibitors have become a key disease-modifying treatment for chronic kidney disease (CKD). A 2025 meta-analysis published in JAMA found that CKD progression occurred at a rate of about 25 events per 1,000 patient-years with SGLT2 inhibitors versus roughly 40 events per 1,000 patient-years with placebo, corresponding to about a 38% lower risk. The drugs also reduced the risk of kidney failure alone by about a third and cut serious acute kidney injury by about a quarter.4JAMA. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis
These benefits hold across a range of kidney function levels. An earlier meta-analysis found a 30% reduction in poor kidney outcomes among patients whose kidney filtration rate was already below 60 (a level considered moderately impaired), and an even larger 43% reduction in those with heavy protein spillage in the urine.5PubMed Central. Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis The protective effect works independently of whether diabetes is present, which is why nephrologists now prescribe these drugs for CKD patients without diabetes as well.6PubMed Central. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
The Kidney Dip That Alarms Patients
One of the most common sources of worry when starting an SGLT2 inhibitor is a dip in your estimated kidney filtration rate (eGFR) on the first blood test after starting the drug. This happens to the majority of patients: one large study found that about 63% experienced some decline, with the average drop being about 3.5 points on the eGFR scale.7PubMed Central. Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level If you see your numbers go down and panic, you are not alone. But this dip is actually a sign that the drug is doing what it is supposed to do.
The drop reflects a reduction in pressure inside the kidney’s filtering units. SGLT2 inhibitors cause the kidney to sense more sodium arriving at a checkpoint called the macula densa. That signal triggers the constriction of the tiny artery feeding each filtering unit, which lowers the pressure inside it.8Endocrinology and Metabolism. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis On paper, the kidney looks like it is filtering less. In reality, the drug has relieved the destructive high-pressure state that was slowly burning out the kidney’s filters.
The reassuring evidence comes from tracking patients over time. A meta-analysis found that patients who experienced this initial dip actually had less annual decline in kidney function afterward compared to those who did not dip, by roughly 0.6 points per year.9Diabetes & Metabolism Journal. Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis The patients with the biggest initial dip (more than 10%) saw the most preservation of long-term function. Doctors who understand this pattern will often counsel patients not to stop the medication based on an early lab result alone.
Side Effects Worth Knowing About
No drug this effective comes without trade-offs. The most common side effect is genital yeast infections, driven by the extra glucose in urine creating a favorable environment for fungal growth. A large matched-cohort study comparing SGLT2 inhibitor users with users of a different diabetes drug class found roughly a threefold increase in genital infection risk. The absolute burden was heavier for women: about 87 extra infections per 1,000 person-years, compared to about 12 extra per 1,000 person-years in men. People over 60 faced an even steeper relative risk.10PubMed Central. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors A separate study confirmed the elevated mycotic infection risk across multiple SGLT2 inhibitor formulations, with women again more affected.11PubMed Central. Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis For most people, these infections are mild and treatable, but they are frequent enough to be worth discussing with your doctor before starting.
A rarer but more serious concern is euglycemic diabetic ketoacidosis (euDKA), a condition where dangerous levels of ketones build up in the blood even though blood sugar is normal or only slightly elevated. The normal-sugar presentation is the dangerous part, because it makes the condition easy to miss. Data from major outcome trials suggest the overall rate of DKA is low, but reviews have noted the rate may be underestimated in clinical practice because the atypical presentation leads to delayed recognition.12Expert Opinion on Drug Safety. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment Situations that increase risk include surgery, prolonged fasting, heavy alcohol use, and very low-carbohydrate diets. Most prescribers advise stopping the drug a few days before any planned surgery.
The Fournier’s Gangrene and Amputation Scares
Two alarming safety signals made headlines early in the SGLT2 inhibitor era: Fournier’s gangrene (a severe soft-tissue infection of the genital area) and lower-limb amputations. Both prompted FDA warnings. But the evidence has evolved considerably since those initial reports.
For Fournier’s gangrene, a nested case-control study comparing SGLT2 inhibitor users with patients on other diabetes medications found no statistically significant increase in risk. The adjusted odds were actually numerically lower in the SGLT2 inhibitor group, though the confidence interval was wide enough that the finding was not definitive either way.13PubMed Central. SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study The amputation signal came specifically from one trial program (CANVAS, studying canagliflozin), and subsequent trials with other SGLT2 inhibitors did not replicate the finding.14PubMed. An update on the safety of SGLT2 inhibitors As a result, the concern about amputations appears to have been either drug-specific or a statistical anomaly, though clinicians remain cautious in patients with existing peripheral vascular disease.
Weight Loss Without Trying
Because SGLT2 inhibitors cause you to urinate out glucose that would otherwise stay in the body, they create a caloric deficit. Typical weight loss is modest, generally a few kilograms, but it is consistent and does not require changes to diet or exercise. A systematic review looking specifically at people with obesity but without diabetes found weight loss in every study examined.15PubMed Central. Weight Loss Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Obesity Without Diabetes: A Systematic Review The weight loss tends to plateau after several months as the body adjusts caloric intake to partially compensate. One review noted that the weight loss occurs without a reduction in basal metabolic rate, in part because the body ramps up non-shivering thermogenesis (heat production by tissues like brown fat) to compensate for the lost calories.16PubMed Central. Kidney-Protective Effects of SGLT2 Inhibitors
Uric Acid, Gout, and Other Metabolic Bonuses
SGLT2 inhibitors lower uric acid levels in the blood by both reducing its production and increasing its excretion through the kidneys. The effect is clinically meaningful: a review in the Journal of the American College of Cardiology reported that these drugs lower serum uric acid by roughly 0.6 to 1.5 mg/dL and reduce the risk of gout by 30% to 50% in large trials.17PubMed. Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week For patients who have both diabetes (or heart failure) and gout, this is a meaningful perk that can reduce the need for separate uric acid-lowering therapy.18PubMed. Uric acid and the cardio-renal effects of SGLT2 inhibitors
Another quietly interesting effect is a rise in hematocrit, the proportion of your blood made up of red blood cells. A meta-analysis found that SGLT2 inhibitors increase hematocrit by about 1.3 percentage points compared to placebo.19PubMed. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis Initially, researchers assumed this was simple hemoconcentration from the diuretic effect, essentially less water in the blood making the red cells look more concentrated. But there is growing evidence that the drugs actually stimulate the kidneys to produce more erythropoietin, the hormone that drives red blood cell production, by relieving low-level oxygen deprivation in the kidney tissue.20PubMed. Increase in hematocrit with SGLT-2 inhibitors – Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia? This may partly explain the heart failure benefits, since better oxygen-carrying capacity helps a struggling heart.
Fatty Liver Disease
Given the metabolic improvements SGLT2 inhibitors produce, researchers have investigated whether they help with fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease). In diabetic patients, there is evidence of benefit: the EMPA-REG OUTCOME trial showed a reduction in liver enzymes with empagliflozin, and a meta-analysis of ten randomized trials confirmed that SGLT2 inhibitors outperformed other diabetes drugs in improving liver and metabolic markers.21ClÃnica Gastroenterológica de México. Pharmacological treatment of steatotic liver disease associated with metabolic dysfunction
The picture in non-diabetic patients is less encouraging. A systematic review and meta-analysis of SGLT2 inhibitors in non-diabetic fatty liver disease found no statistically significant improvement in liver fat content, liver stiffness, or fibrosis scores.22PubMed Central. Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis The evidence base is small, and larger trials may eventually tell a different story, but for now there is no strong case for prescribing SGLT2 inhibitors solely to treat fatty liver in someone without diabetes or another established indication.
SGLT2 Inhibitors in Type 1 Diabetes
These drugs were designed for type 2 diabetes, but the appeal of using them in type 1 is obvious: they reduce blood sugar without insulin, lower insulin requirements, smooth out glucose variability, and help with weight. Studies in type 1 patients have confirmed those benefits, including increased time spent in the target glucose range and reduced daily insulin doses.23PubMed Central. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems – A Literature Review
The problem is ketoacidosis risk. People with type 1 diabetes already have a higher baseline risk for DKA because they produce little or no insulin, and adding a drug that promotes ketone production makes that worse. Clinical trials of sotagliflozin and empagliflozin in type 1 patients reported higher DKA rates compared to placebo. One exception was dapagliflozin in patients with a body mass index of 27 or above, where DKA rates were not significantly increased, possibly because higher body fat provides a metabolic buffer. Regulatory agencies in most countries have not approved SGLT2 inhibitors for type 1 diabetes, though some endocrinologists prescribe them off-label in carefully selected patients with close monitoring.
Combining With GLP-1 Receptor Agonists
SGLT2 inhibitors and GLP-1 receptor agonists (drugs like semaglutide and liraglutide) work through different mechanisms, and there is strong rationale for using them together. SGLT2 inhibitors mainly affect the kidneys and heart through fluid balance and metabolic shifts, while GLP-1 drugs primarily reduce appetite, slow gastric emptying, and exert anti-inflammatory effects on blood vessels. A review of the combination found improvements in blood sugar control, body weight, and blood pressure beyond what either drug achieves alone.24PubMed Central. SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Perhaps more importantly, because the cardiovascular protection appears to work through different pathways (hemodynamic for SGLT2 inhibitors, anti-atherogenic for GLP-1s), there is reason to think the combination may reduce heart attacks, strokes, and heart failure more than either class alone.25PubMed Central. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor This pairing has become increasingly common in clinical practice for high-risk patients, especially those with both diabetes and established cardiovascular or kidney disease.
Dual SGLT1/SGLT2 Inhibitors
Most SGLT2 inhibitors on the market (empagliflozin, dapagliflozin, canagliflozin) are selective for the SGLT2 protein in the kidneys. But there is a related protein, SGLT1, that handles glucose absorption in the gut. Sotagliflozin is the first approved drug that inhibits both. Blocking SGLT1 in the intestine means less glucose gets absorbed from a meal, producing a larger drop in blood sugar after eating. It also triggers the gut to release more GLP-1, the same appetite-regulating hormone that GLP-1 receptor agonist drugs mimic.26PubMed. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
Sotagliflozin’s dual action provides both the kidney-level glucose dumping of a standard SGLT2 inhibitor and the gut-level glucose blocking of SGLT1 inhibition, offering cardiovascular and kidney protection alongside improved post-meal glucose control.27PubMed. A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor As kidney function declines, SGLT2 inhibitors become less effective because less glucose reaches the kidney’s filters, but the SGLT1 gut action of sotagliflozin continues to work regardless of kidney function. This may make it a better option for patients with advanced CKD.
The Caloric Restriction Mimicry Idea
One of the more intriguing areas of SGLT2 inhibitor research is the idea that these drugs mimic some effects of caloric restriction at the cellular level. Caloric restriction, the deliberate reduction of food intake without malnutrition, is one of the most robust interventions for extending lifespan in laboratory animals. SGLT2 inhibitors create a caloric deficit through glucose loss, and the body’s response involves a metabolic shift toward burning fat and producing ketones that resembles starvation signaling.28PubMed Central. Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
This metabolic shift dampens nutrient-sensing pathways that promote cell growth and inflammation when nutrients are abundant, while activating repair and recycling pathways like autophagy, where cells break down damaged components and reuse the parts.29Endocrinology. SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases Whether this translates into measurable anti-aging benefits in humans is unknown, and the analogy to caloric restriction has limits since people on SGLT2 inhibitors are generally eating normally and the caloric deficit is modest. Still, the overlap in pathway activation has generated real interest in whether these drugs could be useful in age-related conditions beyond diabetes, heart failure, and kidney disease.
Cost and Access Around the World
Despite their benefits, SGLT2 inhibitors remain out of reach for many of the people who need them most. A cross-country study found that while these drugs were generally more affordable than GLP-1 receptor agonists, monthly treatment costs still created a substantial financial burden in lower-middle-income countries, contributing to worldwide disparities in diabetes care.30BMJ Open. Availability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study
A modeling study estimated that SGLT2 inhibitors would be cost-effective in low- and middle-income countries at a median price of about $224 per person per year, which would require roughly a 17% reduction from current prices. To achieve actual cost savings for healthcare systems, prices would need to drop by about 21%.31PubMed. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis The analysis noted that SGLT2 inhibitors hold particular promise for reducing diabetes complications and meeting reasonable price targets, especially when used in patients with established cardiovascular or kidney disease, where the benefit per dollar spent is highest. In wealthier countries, generic versions of some SGLT2 inhibitors are beginning to appear, which should gradually widen access, but global equity in diabetes care remains a long way off.